Date Title
July 4, 2018
Realm Therapeutics - SEC registration effective NASDAQ listing approved
RNS Number : 5069T Realm Therapeutics PLC 04 July 2018   Realm Therapeutics Announces U.S. SEC Declares Registration Statement Effective and NASDAQ Approves Listing of ADSs Representing Ordinary Shares   MALVERN, PA , July 4, 2018 - Realm Therapeutics plc (AIM: RLM; Nasdaq: RLM) (the "Company") a
June 14, 2018
Realm Therapeutics - Result of AGM
RNS Number : 4116R Realm Therapeutics PLC 14 June 2018   Realm Therapeutics Announces Results of 2018 Annual General Meeting   MALVERN, PA , June 14, 2018 - Realm Therapeutics plc (AIM: RLM) a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated
May 31, 2018
Realm Therapeutics - Realm to Present at June Investor Conferences
RNS Number : 7573P Realm Therapeutics PLC 31 May 2018   Realm Therapeutics to Present at June Investor Conferences   MALVERN, PA , May 31, 2018 - Realm Therapeutics plc (AIM:RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today
May 24, 2018
Realm Therapeutics - Enrollment complete for Phase 2 study of PR022
RNS Number : 1054P Realm Therapeutics PLC 24 May 2018   Realm Therapeutics Completes Enrollment in Phase 2 Study of PR022 for Atopic Dermatitis   Company Further Strengthens IP Portfolio with New USPTO Notice of Allowance   Reiterates Plans to File an Initial New Drug (IND) Application for PR022 in
May 23, 2018
Realm Therapeutics - Filing with US SEC to Facilitate Nasdaq Listing
RNS Number : 9552O Realm Therapeutics PLC 23 May 2018   Realm Therapeutics Publicly Files Registration Statement with the U.S. SEC to Facilitate Nasdaq Listing of ADSs Representing Ordinary Shares   MALVERN, PA ,   May 23, 2018 - Realm Therapeutics plc (AIM: RLM) (the Company or Realm), a clinical
May 21, 2018
Realm Therapeutics - Data Presentation at IID 2018
RNS Number : 6495O Realm Therapeutics PLC 21 May 2018     Realm Therapeutics Presents Data Highlighting its Proprietary Immunomodulatory Technology's Potential in Acne and Psoriasis at IID 2018     MALVERN, PA , May 21, 2018 - Realm Therapeutics plc (AIM:RLM), a clinical stage biopharmaceutical
May 2, 2018
Realm Therapeutics - Annual Financial Report Available
RNS Number : 9097M Realm Therapeutics PLC 02 May 2018   Realm Therapeutics plc ("Realm Therapeutics" or the "Company")   Annual Report and Accounts Available   2 May 2018 -   Realm Therapeutics plc  (AIM: RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics for
May 2, 2018
Realm Therapeutics - Final Results
RNS Number : 8258M Realm Therapeutics PLC 02 May 2018   THIS ANNOUNCEMENT IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO OR FROM THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE
May 2, 2018
Realm Therapeutics - Realm Files Registration for Nasdaq Listing of ADS
RNS Number : 8259M Realm Therapeutics PLC 02 May 2018   THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION
April 26, 2018
Realm Therapeutics - Notice of Results
RNS Number : 2760M Realm Therapeutics PLC 26 April 2018   Realm Therapeutics plc ("Realm Therapeutics", "Realm", or the "Company")   Notice of Full Year 2017 Results     April 26, 2018 - Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on developing novel
Displaying 11 - 20 of 136

Search Investor Relations